

PRESS RELEASE

Indoco's Q4FY19 Revenues at Rs. 245 Crores

Mumbai, 29th May 2019: Indoco Remedies posted revenues of ₹ 245 crores during the Fourth quarter of FY 2018-19, as against ₹ 259 crores, for the same quarter last year. For the quarter, the Company posted a profit of ₹ 11.6 crores, as against profit of ₹ 20.5 crores, last year.

For the year, the revenues are ₹ 941 crores as against ₹ 1017 crores, last year. The loss for the year stands at ₹ 2.8 crores, as against profit of ₹ 41.2 crores, last year.

Commenting on the 4th quarter results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, "The fourth quarter saw the regulatory challenges easing out, which will pave the way for international business revival. This coupled with promising growth prospects in the India Business, will bring a turnaround for the Company".

For the quarter ended Mar'19, the financials are as under:

(₹ in Crores)

Particulars	Jan'19 - Mar'19	Jan'18 - Mar'18
Net Revenues	245	259
EBIDTA	28.5	49.4
Operating Profit	17.6	38.5
Profit After Tax	11.6	20.5
EPS (Face value ₹ 2/-) (Not annualized)	1.26	2.22

For the year ended Mar'19, the financials are as under:

(₹ in Crores)

Particulars	18-19	17-18
Net Revenues	941	1017
EBIDTA	76.7	134.9
Operating Profit	36.1	97.1
Profit After Tax	(2.8)	41.2
EPS (Face value ₹ 2/-)	(0.31)	4.47

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 5500 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensiform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com